Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
182.89B
Market cap182.89B
Price-Earnings ratio
24.79
Price-Earnings ratio24.79
Dividend yield
2.97%
Dividend yield2.97%
Average volume
1.70M
Average volume1.70M
High today
$343.05
High today$343.05
Low today
$331.00
Low today$331.00
Open price
$333.88
Open price$333.88
Volume
1.60M
Volume1.60M
52 Week high
$346.38
52 Week high$346.38
52 Week low
$259.35
52 Week low$259.35

Stock Snapshot

With a market cap of 182.89B, Amgen(AMGN) trades at $339.64. The stock has a price-to-earnings ratio of 24.79 and currently yields dividends of 3.0%.

On 2026-01-07, Amgen(AMGN) stock moved within a range of $331.00 to $343.05. With shares now at $339.64, the stock is trading +2.6% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 1.6M, compared to an average daily volume of 1.7M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $346.38 and a low of $259.35.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $346.38 and a low of $259.35.

AMGN News

Benzinga 23m
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines. The...

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
TipRanks 3h
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Nasdaq 4h
Dow Movers: JPM, AMGN

In early trading on Wednesday, shares of Amgen topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.6%. Year to da...

Dow Movers: JPM, AMGN

Analyst ratings

48%

of 33 ratings
Buy
48.5%
Hold
42.4%
Sell
9.1%

More AMGN News

Nasdaq 6h
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 million. The acquisition will stre...

Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
Simply Wall St 9h
Amgen Is Increasing Its Dividend To $2.52

Amgen Inc. ( ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52. The payment will take the dividend yield to 3.1%, wh...

Amgen Is Increasing Its Dividend To $2.52
TipRanks 22h
Amgen assumed at Buy from Neutral at UBS

UBS upgraded Amgen (AMGN) to Buy from Neutral with a price target of $380, up from $317, as the analyst assumed coverage of the stock. While the firm notes that...

TipRanks 1d
M&A News: Amgen Stock Brightens after $840M Capture of British Cancer-Fighting Biotech Dark Blue

Shares in drug developer Amgen (AMGN) looked brighter today after it bought Dark Blue Therapeutics, a British cancer-fighting biotech for $840 million. Claim 7...

Nasdaq 1d
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal

(RTTNews) - Amgen, Inc. (AMGN) announced Tuesday its acquisition of UK-based privately-held biotechnology company Dark Blue Therapeutics Ltd. in a transaction v...

Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal
TipRanks 1d
Amgen acquires Dark Blue Therapeutics in deal valued at up to $840M

Amgen (AMGN) announced its acquisition of Dark Blue Therapeutics, a privately held biotechnology company based in the United Kingdom advancing first-in-class, s...

Nasdaq 5d
Axsome Stock Jumps 22.8%: Will It Continue to Soar?

Axsome Therapeutics (AXSM) shares rallied 22.8% in the last trading session to close at $182.64. This move can be attributable to notable volume with a higher n...

Axsome Stock Jumps 22.8%: Will It Continue to Soar?

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.